Amygdala Neurosciences secured FDA IND approval for ANS-858, a selective, reversible, orally bioavailable ALDH2 inhibitor. The program initially targets alcohol use disorder and substance use disorders, with plans to use the Phase 1 dataset as a springboard into broader Phase 2 evaluations across additional indications. The IND clearance advances the company’s effort to translate ALDH2 modulation into a clinically practical CNS-active approach, leveraging an oral small-molecule design. Amygdala said it will start a Phase 1 trial intended to support subsequent indication expansion. For investors and pharma partners, the approval adds another entry into the growing alcohol-use and SUD pipeline where CNS tolerability and dosing convenience are recurring differentiators.